Health · Medical Research · 3 hrs ago
Semaglutide and teduglutide reduced immune-driven gut damage in mice
A study in mice found that semaglutide and teduglutide reduced immune-driven intestinal damage.
The researchers triggered gut injury with an antibody that activates T cells, a type of immune cell.
Mice with missing gut hormone signals were more vulnerable, with different changes including inflammation, loss of intestinal cells and damage to the gut lining.
The medicines activate GLP-1 and GLP-2 receptors, which are involved in the effects of hormones released by cells in the gut.
GLP-1 helps regulate blood sugar and appetite, while GLP-2 supports nutrient absorption and the growth and integrity of the intestinal lining.
The findings suggest gut hormones may help limit acute inflammation, but the experiments were conducted in mice and do not establish that these medicines protect people’s intestines.
Semaglutide and teduglutide reduced immune-driven intestinal damage in mice, a study reported.
The medicines activate GLP-1 and GLP-2 receptors, respectively.
Mice lacking these receptors, or intestinal proglucagon, were more susceptible to damage after an immune challenge.
The study examined how gut-derived glucagon-like peptides affect intestinal injury caused by activated T cells.
The findings suggest these hormones may help protect the intestine during acute inflammation.
- Who
- Researchers studying gut-derived glucagon-like peptides in mice.
- What
- Semaglutide and teduglutide reduced intestinal damage caused by CD3ε-targeting antibodies.
- When
- The study was published on 2026-10-22.
- Where
- In mice; the study examined intestinal injury.
- Why
- To investigate whether activating GLP hormone receptors could protect the gut from T cell-induced damage.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Study publication
- 2026-10-22
- Animals studied
- Male mice aged 12 to 16 weeks
- Semaglutide dose
- 2.5 μg/kg
- Teduglutide dose
- 40 μg/kg
- Challenge used
- CD3ε-targeting antibodies